Brookings March 15, 2023
New legislation (H.R. 485) that is currently being debated in the House Energy and Commerce Committee and a letter to the Department of Health and Human Services (HHS) from Republican members of the Senate Finance Committee present a threat to Medicare’s new and already limited ability to negotiate over some high-priced prescription drugs. The language in these documents could prevent the HHS secretary from utilizing invaluable comparative metrics in seeking to deliver better value for Medicare beneficiaries.
The Inflation Reduction Act (IRA, PL 117-169) requires the secretary of Health and Human Services to negotiate the prices of single-source, high-priced drugs that are also high volume, starting with 10 drugs in 2026 and rising to 20 in 2029 and beyond. The...
Today's Sponsors
Today's Sponsor